Achelous Partners

Team

Mark R. Saunders President, New York mark.saunders@achelous.com As President of Achelous Partners, Mark is a leading investment banker to international public and private life science companies. He has a successful history of cross border mergers and acquisitions and cross border joint ventures. Mark has significant expertise in the US listing process and in all forms of financing available to domestic and international companies. He leverages his extensive contacts both on Wall Street and in the international financial markets to maximize financial opportunities for our clients with market makers, international traders, institutional public and private funds and high net worth investors. Mark was general outside legal counsel to Citibank's ADR Division, undertaking over 300 transactions involving non-US companies listing on NASDAQ and the New York Stock Exchange. He was head of Greenberg Traurig's International Corporate Finance Group, where he advised and assisted non-US companies to issue securities in the US capital markets, representing companies from Australia, the United States, Latin America, Europe and Asia. Mark was also a Partner with the US law firms of Brown & Wood and Parker Chapin, specializing in securities and corporate finance. Mark holds a Juris Doctor from New York Law School and is a member of the New York Bar Association.
Artur Aira European Representative, Sweden artur.aira@achelous.com Artur Aira previously served as Executive Vice President and COO of AddLife AB (“AddLife”). AddLife is a spinoff from AddTech AB and is the Nordic market leader in several niche areas of diagnostics, biomedical research and laboratory analysis, as well as medical technology. During his tenure, AddLife grew organically and via acquisitions to over 600 employees with annual sales of over US$250 million and completed a successful IPO in 2016. Prior to AddLife, Mr. Aira held senior level positions at Addtech AB and was President/ CEO of Addtech LifeScience.
Dr. Jan Boesen European Representative, The Netherlands jan.boesen@achelous.com Dr. Jan Boesen focuses on deal origination and developing various corporate strategies for the European market. Using his long-term management experience in the biotech and diagnostic industry, he advises on and supports international mergers and acquisitions. Jan Boesen has over 20 years "hands on" experience in the Life Sciences industry of which 16 years were in executive positions. He obtained his Ph.D. degree at Leiden University in 1992. He held various management positions in clinical development, operations and business development at Introgene (now Crucell-J&J). From 1999-2005, Jan Boesen was CEO of Amsterdam Molecular Therapeutics (AMT) B.V. (now UniQure, a publicly trading company). During this period, AMT brought a gene therapy for lipoprotein lipase (LPL) deficiency (Glybera) to the clinic. In 2012, Glybera became the first gene therapy approved by the European Commission. Furthermore, he was General Manager of BioConnection (spin-off from Organon-MSD) and COO of ISA Pharmaceuticals, a company developing therapeutic vaccines. From 2008-2015 he was CEO of IBL International, which develops, produces and sells immunodiagnostics products. During this period, IBL was transformed into a niche player with 50% increased turnover and 86 employees. In July 2014, IBL International was sold to the Tecan Group (Switzerland) for €29 million by Achelous Partners.
Dr. Katja Neuer European Representative, Germany katja.neuer@achelous.com Dr. Katja Neuer focuses on deal origination in Germany and globally with a focus on the CRO market. She has developed and leverages a very broad network in this industry since 2008. Katja Neuer is a chemist by training and studied at the RWTH Aachen University, Germany. She completed her PhD thesis at the University of Technology in Munich, Germany in the area of analytical chemistry and started her professional career more than 20 years ago in the environmental healthcare sector, with a strong focus on technical chemistry. In 2008 she joined INTERLAB, a leading central laboratory for clinical trials in Germany which was later acquired by Synlab (acquired in 2015 by Cinven). During her tenure at INTERLAB, the client base grew significantly as a result of her network. In 2011, Katja became Director of Business Development at MLM Medical Labs, a Germany based central lab with a focus on clinical trials. During her time at MLM, she built a business development team from scratch and helped grow the company from 20 employees to over 80 employees and double-digit M€ revenue. In December 2019, MLM was sold to the US based life science focused private equity fund, Great Point Partners, LLC, by Achelous Partners.
Prof. Sergi X. Trilla, MD, MBA European Representative, Spain sergi.trilla@achelous.com Prof. Dr. Sergi X. Trilla is a distinguished biopharmaceutical executive and medical doctor with over 30 years of experience in the healthcare industry. He has a proven track record in corporate strategy and business development in Biotech, MedTech and digital health. As the founder and President of Trifermed, Sergi has been instrumental in transforming innovative ideas into market-ready solutions, leveraging his profound understanding of translational medicine. Under his leadership, Trifermed has orchestrated over 200 global strategic partnerships and expanded its operations to North America, establishing headquarters in Cambridge, MA. Sergi’s executive experience includes pivotal roles such as Chief Business Officer at Veru, where he spearheaded international market entries and strategic shifts, and Chief Strategy Officer at Intrommune Therapeutics, where he transformed the company's business model and initiated fundraising efforts. His strategic vision and operational acumen have consistently driven growth and innovation. In addition to his corporate roles, Sergi is an Adjunct Faculty member at the ADA Forsyth Institute in Cambridge, MA, and has been a mentor and educator at ESADE Business School. He also serves as a Senior Business Advisor for HIPRA and MEDISCA, further showcasing his extensive expertise and influence in the healthcare sector. His contributions to the academic and professional communities have been recognized through various awards, including the Trifermed Awards for Social Impact in Health. Sergi’s multidisciplinary expertise, coupled with his passion for advancing healthcare solutions, makes him an invaluable asset to Achelos as it continues to drive innovation in the life science sector.
Prof. Dr. med. Klaus-Peter Wilhelm European Representative, Germany klaus.wilhelm@achelous.com Dr. Wilhelm has significant expertise in the life sciences field in general and in the area of dermatology contract research in particular. Dr. Wilhelm joins Achelous Partner from proderm, which he founded in 1994. Under his leadership as owner and CEO, proderm was highly profitable and grew organically to over 100 employees and became one of the leading dermatology CROs in the world. Achelous advised proderm on its sale in 20222 to a strategic investor, SGS AG, with nearly 100,000 employees worldwide.
Dr. Stephan Wnendt European Representative, Germany stephan.wnendt@achelous.com Dr. Stephan Wnendt focuses on deal origination in Germany and globally with a focus on clinical trial service providers as well as medical device companies and contract manufacturers. Stephan Wnendt has almost 30 years of experience in various segments of the global life science sector. Since 2000 he has worked in executive positions throughout Germany and the US. After finishing his PhD at the University of Technology in Berlin he joined Grunenthal, a mid-sized pharmaceutical company, where he was responsible for projects on recombinant thrombolytics, immunomodulating drugs and pain research. After Grunenthal, Stephan joined the medical device company, JOMED (now Abbott), as managing director of one their largest production plants. Under his leadership a drug-eluting stent project had been launched. In 2003, Stephan became CEO of the cell therapy company, Kourion Therapeutics. Stephan led Kourion through its merger with ViaCell, Inc. (now Perkin Elmer) and ViaCell's subsequent IPO on NASDAQ. Stephan later served as Managing Director of Paion Deutschland, a biotech company with a focus on neurological diseases. In January 2008, Stephan joined Germany based MLM Medical Labs, a central lab focused on clinical trials. At that time, MLM had six employees and a limited client base. Under Stephan’s leadership, the company grew to over 80 employees and double-digit M€ revenue. In December 2019, MLM was sold to the US based life science focused private equity fund, Great Point Partners, LLC, by Achelous Partners. In addition to his business career, Stephan has completed a habilitation in biochemistry at the RWTH Aachen University in 1999 and was awarded with a honorary professorship in 2012.
Akshay Nadkarni Managing Director, New York akshay.nadkarni@achelous.com Akshay Nadkarni is involved in multiple activities across the firm ranging from leading full sell-side and buy-side M&A transactions to in-depth technology and corporate valuation analysis. Akshay has managed over 25 M&A transactions with a combined transaction value of over $1.2 billion over the past ten years. He is focused on grasping the key value drivers of international life science clients in order to identify creative strategic M&A opportunities. As part of the M&A team, Akshay has managed cross-border transactions involving companies in several healthcare and life science fields, including life science technologies/tools/reagents, in vitro diagnostics, molecular diagnostics, CRO and other outsourced life science services, biopharmaceuticals, specialty pharmaceuticals, generics and healthcare IT. In addition, he has undertaken research involving emerging companies in various healthcare and biotechnology sectors. Akshay holds a Bachelor of Arts in Biology and Finance from New York University.
Marius Sava Managing Director, Los Angeles marius.sava@achelous.com Based in Los Angeles, California, Marius Sava has over a decade of investment banking experience in mergers and acquisitions and corporate advisory. Marius has directly participated in transactions with aggregate value of more than $1 billion. He has advised owner managed and publicly traded companies on a number of transactions including buy side, sell side, negotiated sale, divestiture, and strategic investment mandates. Marius’ advisory experience spans several industries, most notably the life science and healthcare industry in which he specializes. His client list has included leading healthcare corporations such as Ansell, Covance, Life Technologies, Novozymes, and Valeant Pharmaceuticals. Marius is an alumnus of the Stern School of Business at New York University.
Eric L. Zitter Managing Director, New York eric.zitter@achelous.com Eric Zitter focuses on deal origination with a focus on domestic and cross-border mergers and acquisitions. Eric has researched and traveled globally searching for M&A opportunities for Achelous Partners’ international client base. Previously, Eric was a Business Development Analyst at Quintiles Transnational, where he conducted research on potential blockbuster late Phase III/registered drugs as targets for new business opportunities, analyzed competitor companies as targets for possible acquisitions, and launched the company’s first weekly internal newsletter consisting of latest drug news, new drug approvals, and pipeline information. Eric holds a joint Bachelor of Science and Engineering in Bioengineering with a minor in Applied Economics from Cornell University.
Charles P. Tebbetts Vice President charles.tebbetts@achelous.com Since joining Achelous in 2014, Charles Tebbetts has worked on and led numerous M&A transactions including buy-side, sell-side, and cross-border engagements. As a Vice President, Charles has successfully executed on both buy and sale processes, including a publicly listed client on an industry buy-and-build as well as private, founder-owned clients on their competitive sale processes. As a long-term member of Achelous, Charles has become a sector expert in valuation analysis, corporate finance and financial modeling. His broad sector knowledge involves every facet of life science outsourced services, IVD diagnostics, tools and reagents, medtech, medical supply transport and disposal, and much more. Charles graduated in 2014 with a degree in Applied Economics and Management from Cornell University.

Mark R. Saunders
President, New York
mark.saunders@achelous.com

As President of Achelous Partners, Mark is a leading investment banker to international public and private life science companies. He has a successful history of cross border mergers and acquisitions and cross border joint ventures.

Mark has significant expertise in the US listing process and in all forms of financing available to domestic and international companies. He leverages his extensive contacts both on Wall Street and in the international financial markets to maximize financial opportunities for our clients with market makers, international traders, institutional public and private funds and high net worth investors.

Mark was general outside legal counsel to Citibank's ADR Division, undertaking over 300 transactions involving non-US companies listing on NASDAQ and the New York Stock Exchange. He was head of Greenberg Traurig's International Corporate Finance Group, where he advised and assisted non-US companies to issue securities in the US capital markets, representing companies from Australia, the United States, Latin America, Europe and Asia. Mark was also a Partner with the US law firms of Brown & Wood and Parker Chapin, specializing in securities and corporate finance. Mark holds a Juris Doctor from New York Law School and is a member of the New York Bar Association.

Artur Aira
European Representative, Sweden
artur.aira@achelous.com

Artur Aira previously served as Executive Vice President and COO of AddLife AB (“AddLife”). AddLife is a spinoff from AddTech AB and is the Nordic market leader in several niche areas of diagnostics, biomedical research and laboratory analysis, as well as medical technology. During his tenure, AddLife grew organically and via acquisitions to over 600 employees with annual sales of over US$250 million and completed a successful IPO in 2016. Prior to AddLife, Mr. Aira held senior level positions at Addtech AB and was President/ CEO of Addtech LifeScience.

Dr. Jan Boesen
European Representative, The Netherlands
jan.boesen@achelous.com

Dr. Jan Boesen focuses on deal origination and developing various corporate strategies for the European market. Using his long-term management experience in the biotech and diagnostic industry, he advises on and supports international mergers and acquisitions.

Jan Boesen has over 20 years "hands on" experience in the Life Sciences industry of which 16 years were in executive positions. He obtained his Ph.D. degree at Leiden University in 1992. He held various management positions in clinical development, operations and business development at Introgene (now Crucell-J&J). From 1999-2005, Jan Boesen was CEO of Amsterdam Molecular Therapeutics (AMT) B.V. (now UniQure, a publicly trading company). During this period, AMT brought a gene therapy for lipoprotein lipase (LPL) deficiency (Glybera) to the clinic. In 2012, Glybera became the first gene therapy approved by the European Commission. Furthermore, he was General Manager of BioConnection (spin-off from Organon-MSD) and COO of ISA Pharmaceuticals, a company developing therapeutic vaccines. From 2008-2015 he was CEO of IBL International, which develops, produces and sells immunodiagnostics products. During this period, IBL was transformed into a niche player with 50% increased turnover and 86 employees. In July 2014, IBL International was sold to the Tecan Group (Switzerland) for €29 million by Achelous Partners.

Dr. Katja Neuer
European Representative, Germany
katja.neuer@achelous.com

Dr. Katja Neuer focuses on deal origination in Germany and globally with a focus on the CRO market. She has developed and leverages a very broad network in this industry since 2008.

Katja Neuer is a chemist by training and studied at the RWTH Aachen University, Germany. She completed her PhD thesis at the University of Technology in Munich, Germany in the area of analytical chemistry and started her professional career more than 20 years ago in the environmental healthcare sector, with a strong focus on technical chemistry. In 2008 she joined INTERLAB, a leading central laboratory for clinical trials in Germany which was later acquired by Synlab (acquired in 2015 by Cinven). During her tenure at INTERLAB, the client base grew significantly as a result of her network. In 2011, Katja became Director of Business Development at MLM Medical Labs, a Germany based central lab with a focus on clinical trials. During her time at MLM, she built a business development team from scratch and helped grow the company from 20 employees to over 80 employees and double-digit M€ revenue. In December 2019, MLM was sold to the US based life science focused private equity fund, Great Point Partners, LLC, by Achelous Partners.

Prof. Sergi X. Trilla, MD, MBA
European Representative, Spain
sergi.trilla@achelous.com

Prof. Dr. Sergi X. Trilla is a distinguished biopharmaceutical executive and medical doctor with over 30 years of experience in the healthcare industry. He has a proven track record in corporate strategy and business development in Biotech, MedTech and digital health. As the founder and President of Trifermed, Sergi has been instrumental in transforming innovative ideas into market-ready solutions, leveraging his profound understanding of translational medicine.

Under his leadership, Trifermed has orchestrated over 200 global strategic partnerships and expanded its operations to North America, establishing headquarters in Cambridge, MA.

Sergi’s executive experience includes pivotal roles such as Chief Business Officer at Veru, where he spearheaded international market entries and strategic shifts, and Chief Strategy Officer at Intrommune Therapeutics, where he transformed the company's business model and initiated fundraising efforts. His strategic vision and operational acumen have consistently driven growth and innovation.

In addition to his corporate roles, Sergi is an Adjunct Faculty member at the ADA Forsyth Institute in Cambridge, MA, and has been a mentor and educator at ESADE Business School. He also serves as a Senior Business Advisor for HIPRA and MEDISCA, further showcasing his extensive expertise and influence in the healthcare sector. His contributions to the academic and professional communities have been recognized through various awards, including the Trifermed Awards for Social Impact in Health.

Sergi’s multidisciplinary expertise, coupled with his passion for advancing healthcare solutions, makes him an invaluable asset to Achelos as it continues to drive innovation in the life science sector.

Prof. Dr. med. Klaus-Peter Wilhelm
European Representative, Germany
klaus.wilhelm@achelous.com

Dr. Wilhelm has significant expertise in the life sciences field in general and in the area of dermatology contract research in particular. Dr. Wilhelm joins Achelous Partner from proderm, which he founded in 1994. Under his leadership as owner and CEO, proderm was highly profitable and grew organically to over 100 employees and became one of the leading dermatology CROs in the world. Achelous advised proderm on its sale in 20222 to a strategic investor, SGS AG, with nearly 100,000 employees worldwide.

Dr. Stephan Wnendt
European Representative, Germany
stephan.wnendt@achelous.com

Dr. Stephan Wnendt focuses on deal origination in Germany and globally with a focus on clinical trial service providers as well as medical device companies and contract manufacturers.

Stephan Wnendt has almost 30 years of experience in various segments of the global life science sector. Since 2000 he has worked in executive positions throughout Germany and the US. After finishing his PhD at the University of Technology in Berlin he joined Grunenthal, a mid-sized pharmaceutical company, where he was responsible for projects on recombinant thrombolytics, immunomodulating drugs and pain research. After Grunenthal, Stephan joined the medical device company, JOMED (now Abbott), as managing director of one their largest production plants. Under his leadership a drug-eluting stent project had been launched. In 2003, Stephan became CEO of the cell therapy company, Kourion Therapeutics. Stephan led Kourion through its merger with ViaCell, Inc. (now Perkin Elmer) and ViaCell's subsequent IPO on NASDAQ. Stephan later served as Managing Director of Paion Deutschland, a biotech company with a focus on neurological diseases. In January 2008, Stephan joined Germany based MLM Medical Labs, a central lab focused on clinical trials. At that time, MLM had six employees and a limited client base. Under Stephan’s leadership, the company grew to over 80 employees and double-digit M€ revenue. In December 2019, MLM was sold to the US based life science focused private equity fund, Great Point Partners, LLC, by Achelous Partners.

In addition to his business career, Stephan has completed a habilitation in biochemistry at the RWTH Aachen University in 1999 and was awarded with a honorary professorship in 2012.

Akshay Nadkarni
Managing Director, New York
akshay.nadkarni@achelous.com

Akshay Nadkarni is involved in multiple activities across the firm ranging from leading full sell-side and buy-side M&A transactions to in-depth technology and corporate valuation analysis.

Akshay has managed over 25 M&A transactions with a combined transaction value of over $1.2 billion over the past ten years. He is focused on grasping the key value drivers of international life science clients in order to identify creative strategic M&A opportunities. As part of the M&A team, Akshay has managed cross-border transactions involving companies in several healthcare and life science fields, including life science technologies/tools/reagents, in vitro diagnostics, molecular diagnostics, CRO and other outsourced life science services, biopharmaceuticals, specialty pharmaceuticals, generics and healthcare IT. In addition, he has undertaken research involving emerging companies in various healthcare and biotechnology sectors. Akshay holds a Bachelor of Arts in Biology and Finance from New York University.

Marius Sava
Managing Director, Los Angeles
marius.sava@achelous.com

Based in Los Angeles, California, Marius Sava has over a decade of investment banking experience in mergers and acquisitions and corporate advisory. Marius has directly participated in transactions with aggregate value of more than $1 billion. He has advised owner managed and publicly traded companies on a number of transactions including buy side, sell side, negotiated sale, divestiture, and strategic investment mandates. Marius’ advisory experience spans several industries, most notably the life science and healthcare industry in which he specializes. His client list has included leading healthcare corporations such as Ansell, Covance, Life Technologies, Novozymes, and Valeant Pharmaceuticals.

Marius is an alumnus of the Stern School of Business at New York University.

Eric L. Zitter
Managing Director, New York
eric.zitter@achelous.com

Eric Zitter focuses on deal origination with a focus on domestic and cross-border mergers and acquisitions. Eric has researched and traveled globally searching for M&A opportunities for Achelous Partners’ international client base.

Previously, Eric was a Business Development Analyst at Quintiles Transnational, where he conducted research on potential blockbuster late Phase III/registered drugs as targets for new business opportunities, analyzed competitor companies as targets for possible acquisitions, and launched the company’s first weekly internal newsletter consisting of latest drug news, new drug approvals, and pipeline information. Eric holds a joint Bachelor of Science and Engineering in Bioengineering with a minor in Applied Economics from Cornell University.

Charles P. Tebbetts
Vice President
charles.tebbetts@achelous.com

Since joining Achelous in 2014, Charles Tebbetts has worked on and led numerous M&A transactions including buy-side, sell-side, and cross-border engagements. As a Vice President, Charles has successfully executed on both buy and sale processes, including a publicly listed client on an industry buy-and-build as well as private, founder-owned clients on their competitive sale processes. As a long-term member of Achelous, Charles has become a sector expert in valuation analysis, corporate finance and financial modeling. His broad sector knowledge involves every facet of life science outsourced services, IVD diagnostics, tools and reagents, medtech, medical supply transport and disposal, and much more.

Charles graduated in 2014 with a degree in Applied Economics and Management from Cornell University.

Overview
New York-based investment bank focused on Mergers and Acquisitions in the global life science and healthcare sectors.

Global Presence
Building management relationships throughout the US, Europe, Australia, Asia and Latin America.

Approach
Cultivating long-term relationships through senior-level attention and expertise, objective advice and successful deal execution.

Recent News

June 12, 2024 Prof. Dr. Sergi X. Trilla joins Achelous Partners as European Representative
June 12, 2024 Achelous Partners Advises Curia on its announced sale of a US CDMO site to Siegfried
April 22, 2024 Achelous Partners Advises A4P Consulting Ltd on its sale to LabConnect

June 12, 2024
Prof. Dr. Sergi X. Trilla joins Achelous Partners as European Representative

June 12, 2024
Achelous Partners Advises Curia on its announced sale of a US CDMO site to Siegfried

April 22, 2024
Achelous Partners Advises A4P Consulting Ltd on its sale to LabConnect

June 2024

Wisconsin CDMO site is being acquired by

The undersigned acted as financial advisor to Curia Global Inc.
April 2024

has been acquired by

The undersigned acted as financial advisor to A4P Consulting
March 2024

has been acquired by

The undersigned acted as financial advisor to Six Degrees Medical
December 2023

has been acquired by

The undersigned acted as financial advisor to Bio X Cell, LLC
November 2023

has been acquired by

The undersigned acted as financial advisor to Symbio LLC
November 2023

has been acquired by

The undersigned acted as financial advisor to Proinnovera, GmbH
November 2023

has been acquired by

The undersigned acted as financial advisor to Pharmalog, GmbH
January 2023

has been acquired by

The undersigned acted as financial advisor to ECIR Medical Communications Inc.
January 2023

has been acquired by

The undersigned acted as financial advisor to Alcedis, GmbH
November 2022

has been acquired by

The undersigned acted as financial advisor to Expression Systems, LLC
October 2022

has been acquired by

The undersigned acted as financial advisor to AQW Holdings, Inc. d.b.a. Qfix
August 2022

has been acquired by

The undersigned acted as financial advisor to AusDiagnostics
July 2022

has been acquired by

The undersigned acted as financial advisor to Cergentis B.V.
July 2022

has been acquired by

The undersigned acted as financial advisor to proderm GmbH
June 2022

has been acquired by

The undersigned acted as financial advisor to SAI MedPartners
February 2022

has acquired

The undersigned acted as financial advisor to TCP Analytical
November 2021

has been acquired by

The undersigned acted as financial advisor to Regulatory Compliance Associates Inc.
August 2021

has been acquired by

The undersigned acted as financial advisor to DRG International Inc.
August 2021

has been acquired by

The undersigned acted as financial advisor to bioskin GmbH
July 2021

has been acquired by

The undersigned acted as financial advisor to nanoComposix Holdings, Inc.
May 2021

has been acquired by

The undersigned acted as financial advisor to Clinical Outcomes Solutions
March 2021

has been acquired by

The undersigned acted as financial advisor to Diamond Pharma Services
February 2021

has been acquired by

The undersigned acted as financial advisor to Delphi Genetics
October 2020

has been acquired by

The undersigned acted as financial advisor to MD Biosciences, Inc.
September 2020

has been acquired by

The undersigned acted as financial advisor to American Laboratory Products Company, Ltd.
September 2020

has been acquired by

The undersigned acted as financial advisor to Maetrics LLC
August 2020

has been acquired by

The undersigned acted as financial advisor to CTK Biotech, Inc.
February 2020

has been acquired by

The undersigned acted as financial advisor to BresMed Health Solutions Ltd
January 2020

has been acquired by

The undersigned acted as financial advisor to Statistics Collaborative, Inc.
December 2019

has been acquired by

The undersigned acted as financial advisor to MLM Medical Labs GmbH
October 2019

has been acquired by

The undersigned acted as financial advisor to Specialized Medical Services-oncology BV
July 2019

has been acquired by

The undersigned acted as financial advisor to Eurolyser Diagnostica GmbH
July 2019

has acquired

The undersigned acted as financial advisor to LifeSpan BioSciences
March 2019

has been acquired by

The undersigned acted as financial advisor to Quorum Review, Inc.
January 2019

has been acquired by

The undersigned acted as financial advisor to ProductLife Group
January 2019

has been acquired by

The undersigned acted as financial advisor to CoreBiome, Inc.
October 2018

has been acquired by

The undersigned acted as financial advisor to Pennside Partners Ltd.
September 2018

has been acquired by

The undersigned acted as financial advisor to NovaTec Immundiagnostica GmbH
September 2018

has acquired

The undersigned acted as financial advisor to Thompson Street Capital Partners
September 2018

has been acquired by

The undersigned served as financial advisor to HyTest Ltd.
July 2018

has been acquired by

The undersigned served as financial advisor to Gold Standard Diagnostics Corp.
May 2018

has been acquired by

The undersigned served as financial advisor to Biovian Oy
January 2018

has been acquired by

The undersigned served as financial advisor to LifeCodexx AG
June 2017

has been acquired by

The undersigned acted as financial advisor to Coté Orphan, LLC
May 2017

has been acquired by

The undersigned acted as financial advisor to PharmaCell B.V.
April 2017

has been acquired by

The undersigned acted as financial advisor to Emergo Group, Inc.
April 2017

has been acquired by

The undersigned acted as financial advisor to Calbiotech, Inc.
January 2017

has been acquired by

The undersigned acted as financial advisor to BioControl Systems, Inc.
August 2016

has been acquired by

The undersigned acted as financial advisor to SPEware Corporation
July 2016

has acquired

The undersigned acted as financial advisor to Sharps Compliance Corp.
June 2016

has been acquired by

The undersigned acted as financial advisor to Cisbio Bioassays
December 2015

has acquired

The undersigned acted as financial advisor to Abzena plc
December 2015

has acquired

The undersigned acted as financial adviser to Sharps Compliance Corp.
October 2015

has been acquired by

The undersigned acted as financial advisor to Kinesis Pharma BV
August 2015

has been acquired by

The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
July 2015

has acquired

The undersigned acted as financial advisor to Sharps Compliance Corp.
March 2015

has acquired

The undersigned acted as financial advisor to Ansell Limited
July 2014

has been acquired by

The undersigned acted as financial advisor to IBL International Holding BV
July 2014

has been acquired by

The undersigned served as financial advisor to Phlexglobal Limited
June 2014

has been acquired by

The undersigned served as financial advisors to Pharmalink Consulting
December 2013

has acquired assets from

The undersigned acted as advisor to Valeant Pharmaceuticals International
August 2013

has been acquired by

The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
July 2013

has been acquired by

The undersigned acted as financial advisor to The Anson Group LLC
July 2013

has signed a definitive agreement to sell its orthopedic implant assets and business to

an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
July 2013

has been acquired by

The undersigned acted as financial advisor to Kreatech Holding B.V.
July 2013

has been acquired by

USD$10,000,000

The undersigned acted as financial advisor to Matrical Bioscience Inc
May 2013

has been acquired by

The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
August 2012

has been acquired by

The undersigned acted as advisor to JSW Life Sciences GmbH
March 2012

has acquired assets from

US$164M plus up to US$20M in milestones

The undersigned acted as advisor to Valeant Pharmaceuticals International
December 2011

invests in

The undersigned acted as advisor to Ansell Limited for the investment
August 2010

has been acquired by

The undersigned acted as financial advisor to EnviroLogix, Inc.
March 2010

has been acquired by

USD$59,000,000

The undersigned acted as financial advisor to Finnzymes Oy
December 2009

has licensed its ReGet® drug delivery system for ophthalmic indications to

The undersigned acted as financial advisor to BTG olc
October 2009

has been acquired by

The undersigned acted as financial advisor to Anaspec Inc.
August 2009

has sold its HySolv™ drug delivery technology to

The undersigned acted as financial advisor to BTG plc
January 2009

has been acquired by

The undersigned acted as financial advisor to the shareholders of Labcoat Limited
December 2008

has acquired

The undersigned is acting as financial advisor to Biocompatibles International
December 2008

has acquired

The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
February 2008

has been acquired by

The undersigned is acting as financial advisor to Sigma Pharmaceuticals
January 2008

has been acquired by

The undersigned is acting as financial advisor to Panbio Limited
May 2007

has acquired

The undersigned acted as financial advisor to Ansell Limited
March 2007

has sold its Human Health point-of-care diagnostic products business to

The undersigned acted as financial advisor to Agenix Limited
February 2007

Strategic alliance and investment of up to £32,100,000 in

The undersigned acted as financial advisor to GeneMedix, PLC
December 2006

Announced M&A advisory and restructuring

The undersigned acted as financial advisor to Panbio Limited
December 2006

has acquired

The undersigned acted financial advisor to Novozymes A/S
August 2006

has acquired

The undersigned acted as financial advisor to Meditech Research Limited
July 2006

has acquired Delta Biotechnology Ltd from

The undersigned acted as financial advisor to Novozymes A/S
April 2006

has assigned IP and granted distribution rights for its Animal Health business to

The undersigned acted as financial advisor to Agenix Limited
October 2005

M&A advisory and valuation analysis

The undersigned acted as financial advisor to CogState Limited
September 2005

NASDAQ listing of ADRs (American Depositary Receipts)

The undersigned acted as advisor to Genetic Technologies Limited
June 2005

NASDAQ listing of ADRs (American Depositary Receipts)

The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
January 2005

awarded to

for its investment banking role in the creation of
December 2004

has been acquired by

The undersigned acted as financial advisor to AGT Biosciences Ltd.

Top